Physiologic characterization of the chronic bronchitis phenotype in GOLD Grade IB COPD

Chest

Volumn 147, Issue 5, 2015, Pages 1235-1245

  Elbehairy, Amany F ^a,b   Raghavan, Natya ^c   Cheng, Sicheng ^a   Yang, Ling ^a   Webb, Katherine A ^a   Neder, J Alberto ^a   Guenette, Jordan A ^d   Mahmoud, Mahmoud I ^b   O'Donnell, Denis E ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; SHORT ACTING DRUG;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; COUGHING; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DYSPNEA; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; HUMAN CELL; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; MALE; MUCUS SECRETION; OXYGEN CONSUMPTION; PHENOTYPE; PHYSICAL ACTIVITY; PHYSICAL DISABILITY; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; SMALL AIRWAY DISEASE; SPUTUM EXAMINATION; SYMPTOM; CLASSIFICATION; COMPLICATION; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; BRONCHITIS, CHRONIC; CROSS-SECTIONAL STUDIES; EXERCISE TEST; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 84929501031     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-1491     Document Type: Article

References (63)

1. Agustí A, Calverley PM, Celli B, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. R espir Res. 2010 ; 11 : 122-136.
2. Global Initi ative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd.or g/guidelines-globalstrategy-for-diagnosis-management.html. Accessed June, 2014.
3. Wedzicha JA. The heterogeneity of chronic obstructive pulmonary disease. Thorax. 2000 ; 55 (8): 631-632.
4. Agustí AG. COPD, a multicomponent disease: implications for management. Respir Med. 2005 ; 99 (6): 670-682.
5. Han MK , Agustí A , Calverley PM , et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010 ; 182 (5): 598-604.
6. Medical Research Council. Defi nition a nd classifi cation of chronic bronchitis for clinical and epidemiological purposes. Lancet. 1965 ; 1 (7389): 775-779.
7. Sobradillo V , Miravitlles M , Jiménez CA , et al. Epidemiological study of chronic obstructive pulmonary disease in Spain (IBERPOC): prevalence of chronic respiratory symptoms and airfl ow limitation [in Spanish]. Arch Bronconeumol. 1999 ; 35 (4): 159-166.
8. Cerveri I,Accordini S,Verlato G,et al European Community Respiratory Health Survey (ECRHS) Study Group. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. E ur Respir J. 2001 18 1, 85-92.
9. Huchon GJ , Vergnenégre A , Neukirch F , Brami G , Roche N , Preux PM. Chronic bronchitis among French adults: high prevalence and underdiagnosis. Eur Respir J. 2002 ; 20 (4): 806-812.
10. Lundbä ck B , Lindberg A , Lindström M , et al ; Obstructive Lung Disease in Northern Sweden Studies. Not 15 but 50% of smokers develop COPD? Report from the obstructive lung dise ase in northern Sweden studies. Respir Med. 2003 ; 97 (2): 115-122.
11. Miravitlles M , de la Roza C , Morera J , et al. Chronic respiratory symptoms, spirometry and knowledge of COPD among gen eral population. Respir Med. 2006 ; 100 (11): 1973-1980.
12. de Marco R , Accordini S , Cerveri I , et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults ac cording to the presence of chronic cough and phlegm. Am J Respir Crit Care Med. 2007 ; 175 (1): 32-39.
13. Miravitlles M , Soriano JB , García-Río F , et al. Prevalence of COPD in Spain: i mpact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009 ; 64 (10): 863-868.
14. Harmsen L , Th omsen SF , Ingebrigtsen T , et al. Chronic mucus hypersecretion: prevalence and risk factors in younger individuals. Int J Tuberc Lung Dis. 2010 ; 14 (8): 1052-1058.
15. Fletcher C , Peto R. The natural history of chronic airfl ow obstruction. BMJ. 1977 ; 1 (6077): 1645-1648.
16. Vestbo J, Prescott E, Lange P; Copenhagen City Heart Study Group. Association of chronic mucus hypersecretion with FEV 1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med. 1996; 153(5): 1530-1535.
17. Burgel PR , Nesme-Meyer P , Chanez P , et al ; Initiatives Bronchopneumopathie Chronique Obstructive Scientific Committee. Cough and spu tum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009 ; 135 (4): 975-982.
18. Prescott E , Lange P , Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J. 1995 ; 8 (8): 1333-1338.
19. Miravitlles M, Guer rero T, Mayordomo C, Sánchez-Agudo L , Nicolau F , Segú JL ; The EOLO Study Group. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression a nalysis. Respiration. 2000 ; 67 (5): 495-501.
20. Kim V , Han MK , Vance GB , et al ; COPDGene Investigators. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011 ; 140 (3): 626-633.
21. Ekberg-Aronsson M , Pehrsson K , Nilsson JA , Nilsson PM , Löfdahl CG. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res. 2005 ; 6 : 98.
22. Rennard SI, Calverley PM, Goehring UM, Bredenbröker D , Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor rofl umilast-the im portance of defi ning diff erent subsets of patients with COPD. Respir Res. 2011 ; 12 : 18.
23. Wagner PD , Dantzker DR , Dueck R , Clausen JL, West JB. Ventilation-perfusion inequality in c hronic obstructive pulmonary disease. J Clin Invest. 1977 ; 59 (2): 203-216.
24. Burrows B , Fletcher CM , Heard BE , Jones NL , Wootliff JS. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet. 1966 ; 1 (7442): 830-835.
25. Gutierrez C, Ghezzo RH, Abboud RT, et al. Reference values of pulmonary function tests for Canadian Caucasians. Can Respir J. 2004 ; 11 (6): 414-424.
26. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and fi rst v alidation of the COPD Assessment Test. Eur Respir J. 2009 ; 34 (3): 648-654.
27. Fletcher CM , Elmes PC , Fairbairn AS , Wood CH. The signifi cance of respiratory symptoms and the diagno sis of chronic bronchitis in a working population. BMJ. 1959 ; 2 (5147): 257-266.
28. Mahler DA , Weinberg DH , Wells CK , Feinstein AR. The measurement of dyspnea. Contents, interobserve r agreement, and physiologic correlates of two new clinical indexes. C hest. 1984 ; 85 (6): 751-758.
29. Jones PW,Quirk FH,Baveystock CM,Littlejohns P A self-complete measure of health s tatus for chronic airfl ow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992 145, 6, 1321-1327.
30. McGavin CR , Artvinli M , Naoe H , McHardy GJ. Dyspnoea, di sability, and distance walked: comparison of estimates of exercise performance in respiratory disease. BMJ. 1978 ; 2 (6132): 241-243.
31. Stewart AL , Mills KM , King AC , Haskell WL , Gillis D , Ritter PL. CHAMPS physical activity questionnaire for older adults: outcomes for interventions. Med Sci Sports Exerc. 2001 ; 33 (7): 1126-1141.
32. Charlson ME , Pompei P , Ales KL , MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987 ; 40 (5): 373-383.
33. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 ; 26 (2): 319-338.
34. Wa nger J , Clausen JL , Coates A , et al ; on behalf of the ATS/ERS Task Force on Standardisation of Lung Function Testing. Standardisation of the measurement of lung volumes. E ur Respir J. 2005 ; 26 (3): 511-522.
35. Macintyre N , Crapo RO , Viegi G , et al ; on behalf of the ATS/ERS Task Force on Standardisation of Lung Function Testing. Standardisation of the singlebreath determination of carbon monoxide uptake in the lung. Eur Re spir J. 2005 ; 26 (4): 720-735.
36. American Th oracic Society/European Respiratory Society. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med. 2002 ; 166 (4): 518-624.
37. Buist AS. Early detection of airways obstruction by the closing volume technique . Chest. 1973 ; 64 (4): 495-499.
38. Oostveen E , MacLeod D , Lorino H , et al ; ERS Task Force on Respiratory Impedance Measurements. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J. 2003 ; 22 (6): 1026-1041.
39. Morris JF , Koski A , Temple WP , Claremont A , Th omas DR. Fift een-year interval spirometric evaluation of the Oregon predictive equations. Chest. 1988 ; 93 (1): 123-127.
40. Crap o RO , Morris AH , Clayton PD , Nixon CR. Lung volumes in healthy nonsmoking adults. Bull Eur Physiopathol Respir. 1982 ; 18 (3): 419-425.
41. Burrows B , Kasik JE , Niden AH , Barclay WR. Clinical usefulness of the singlebreath pulmonucy diff using capacity test. Am Rev Respir Dis. 1961 ; 84 : 789-806.
42. Briscoe WA, Dubois AB. The relationship between airway resistanc e, airway conductance and lung volume in subjects of diff erent age and body size. J Clin Invest. 1958 ; 37 (9): 1279-1285.
43. Hamilton AL, Killian KJ , Summers E, Jones NL. Muscle streng th, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med. 1995; 152(6 pt 1): 2021-2031.
44. Buist AS , Ross BB. Predicted values for closing volumes using a modifi ed single breath nitrogen test. Am Rev Respir Dis. 1973 ; 107 (5): 744-752.
45. Ofi r D , Laveneziana P , Webb KA , Lam YM , O'Donnell DE. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 ; 177 (6): 622-629.
46. Johnson BD , Weisman IM , Zeballos RJ , Beck KC. Emerging concepts in the evaluation of ventilatory limitation during exercise: the exercise tidal fl ow-volume loop. C hest. 1999 ; 116 (2): 488-503.
47. Paggiaro PL , Chanez P , Holz O , et al. ERS Task force on Sputum Induction. Report of Working Group 1: Sputum Induction. Eur Respir J. 2002; 20(suppl 37): 3s-8s.
48. Eft himiadis A , Spanevello A , Hamid Q , et al. ERS Task force on sputum induction. Report of Working Group 3: methods of sputum processing for cell counts, immunocytochemistry and in situ hybridization. Eur Respir J. 2002; 20(suppl 37): 19s-23s.
49. Coxson HO , Rogers RM , Whittall KP , et al. A quantifi cation of the lung surface area in emphysema using computed tomography. Am J Respir Crit Care Med. 1999 ; 159 (3): 851-856.
50. Gevenois PA, de Maertelaer V, De Vuyst P, Zanen J , Yernault JC. Comparison of computed density and macroscopic morphometry in pulmonary emphysema . Am J Respir Crit Care Med. 1995 ; 152 (2): 653-657.
51. Nakano Y,Wong JC,de Jong PA,et al. The prediction of small airway dimensions using computed tomography Am J Respir Crit Care Med. 2005 171, 2, 142-146.
52. Yuan R, Hogg JC, ParéPD, et al. Prediction of the rate of decline in FEV(1) in smokers using quantitative computed tomography. Thorax. 2009 ; 64 (11): 944-949.
53. Chin RC , Guenette JA , Cheng S , et al. Does the respiratory system limit exercise in mild chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2013 ; 187 (12): 1315-1323.
54. Guenette JA, Jensen D, Webb KA, Ofi r D, Raghavan N, O'Donnell DE. Sex diff erences in exertional dyspnea in patients with mild COPD: physiological mechanisms. Respir Physiol Neurobiol. 2011 ; 177 (3): 218-227.
55. O'Donnell DE, Maltais F, Porszasz J, et al; 205.440 investigators. The continuum of physiological impairment during treadmill walking in patients with mildto-moderate COPD: patient characterization phase of a randomized clinical trial. PLoS ONE. 2014 ; 9 (5): e96574.
56. Barbera JA, Roca J, Ramirez J, Wagner PD, Ussetti P, Rodriguez-Roisin R. Gas exchange during exercise in mild chronic obs tructive pulmonary disease. Correlation with lung structure. A m Rev Respir Dis. 1991 ; 144 (3 pt 1): 520-525.
57. Dantzker DR , D'Alonzo GE. The effect of exercise on pulmonary gas exchange in patients w ith severe chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986 ; 134 (6): 1135-1139.
58. Rodrí guez-Roisin R , Drakulovic M , Rodríguez DA , Roca J , Barberá JA , Wagner PD. Ventilation-perfusion imbalance and chronic obstructive pulmonary disease staging severity. J Appl Physiol (1985). 2009 ; 106 (6): 1902-1908.
59. Gagnon P , Saey D , Vivodtzev I , et al. Impact of preinduced quadriceps fatigue on exercise response in chronic obstructive pulmonary disease and healthy subjects. J Appl Physiol (1985). 2009 ; 107 (3): 832-840.
60. Gagnon P, Bussiéres JS, Ribeiro F, et al. Infl uences of spinal anesthesia on exercise tolerance in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 ;186(7):606-615.
61. Guenette JA , Webb KA , O'Donnell DE. Does dynamic hyperinfl ation contribute to dyspnoea during exercise in patients with COPD? Eur Respir J. 2012 ; 40 (2): 322-329.
62. Tantucci C. Expiratory fl ow limitation defi nition, mechanisms, methods, and signifi cance. P ulm Med. 2013 ; 2013 :749860.
63. Diaz O , Villafranca C , Ghezzo H , et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory fl ow limitation at rest. Eur Respir J. 2000 ; 16 (2): 269-275.